Urban Linei Augusta Brolini Delle, Chala Luciano Fernandes, de Paula Ivie Braga, Bauab Selma di Pace, Schaefer Marcela Brisighelli, Oliveira Ana Lúcia Kefalás, Shimizu Carlos, de Oliveira Tatiane Mendes Gonçalves, Moraes Paula de Camargo, Miranda Beatriz Medicis Maranhão, Aduan Flávia Engel, Rego Salete de Jesus Fonseca, Canella Ellyete de Oliveira, Couto Henrique Lima, Badan Gustavo Machado, Francisco José Luis Esteves, Moraes Thaís Paiva, Jakubiak Rosangela Requi, Peixoto João Emílio
Members of the National Mammography Commission, Representatives of the Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR), São Paulo, SP, Brazil.
Coordinator of the National Mammography Commission of the Colégio Brasileiro de Radiologia e Diagnóstico por Imagem (CBR), São Paulo, SP, Brazil.
Radiol Bras. 2023 Jul-Aug;56(4):207-214. doi: 10.1590/0100-3984.2023.0064-en.
To present an update of the recommendations of the Brazilian College of Radiology and Diagnostic Imaging, the Brazilian Society of Mastology, and the Brazilian Federation of Gynecology and Obstetrics Associations for breast cancer screening in Brazil.
Scientific evidence published between January 2012 and July 2022 was gathered from the following databases: Medline (PubMed); Excerpta Medica (Embase); Cochrane Library; Ebsco; Cumulative Index to Nursing and Allied Health Literature (Cinahl); and Latin-American and Caribbean Health Sciences Literature (Lilacs). Recommendations were based on that evidence and were arrived at by consensus of a joint committee of experts from the three entities.Recommendations: Annual mammographic screening is recommended for women between 40 and 74 years of age. For women at or above the age of 75, screening should be reserved for those with a life expectancy greater than seven years. Women at higher than average risk are considered by category: those with dense breasts; those with a personal history of atypical lobular hyperplasia, classical lobular carcinoma in situ, or atypical ductal hyperplasia; those previously treated for breast cancer; those having undergone thoracic radiotherapy before age 30; and those with a relevant genetic mutation or a strong family history. The benefits of complementary screening are also addressed according to the subcategories above. The use of tomosynthesis, which is an evolved form of mammography, should be considered in screening, whenever accessible and available.
介绍巴西放射学与诊断成像学会、巴西乳腺病学会以及巴西妇产科协会联合会关于巴西乳腺癌筛查建议的最新情况。
收集2012年1月至2022年7月间发表的科学证据，来源如下数据库：医学在线数据库（PubMed）；医学文摘数据库（Embase）；考克兰图书馆；Ebsco；护理及相关健康文献累积索引数据库（Cinahl）；以及拉丁美洲和加勒比健康科学文献数据库（Lilacs）。这些建议基于上述证据，并由这三个实体的专家联合委员会达成共识得出。
建议对40至74岁的女性进行年度乳腺钼靶筛查。对于75岁及以上的女性，仅对预期寿命超过7年的女性进行筛查。将高于平均风险的女性按类别划分：乳房致密的女性；有非典型小叶增生、经典小叶原位癌或非典型导管增生个人病史的女性；曾接受过乳腺癌治疗的女性；30岁之前接受过胸部放疗的女性；以及有相关基因突变或家族病史强烈的女性。还根据上述子类别讨论了补充筛查的益处。在筛查中，只要可及且可用，应考虑使用乳腺断层合成技术，这是乳腺钼靶的一种改进形式。
